Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The bone marrow is a hypoxic microenvironment that is rich in growth factors and blood vessels and is readily colonized by tumor cells disseminated from numerous cancers including tumors of the breast, prostate, lung, and skin. The origin of metastatic growth promoting factors for tumor cells disseminated to the bone marrow is derived from multiple sources: the bone matrix, which is a reservoir for growth factors, and cells residing in the marrow and along bone surfaces, such as osteoblasts, osteoclasts, macrophages, and T cells, which secrete cytokines and chemokines. Low oxygen levels within the bone marrow induce hypoxia signaling pathways such as hypoxia inducible factor (HIF), which is regulated by oxygen requiring prolyl hydroxylases (PHDs) and von Hippel-Lindau (VHL) tumor suppressor. These hypoxia signaling pathways have profound effects on bone development and homeostasis. Likewise, hypoxic conditions observed in local breast and prostate tumors point to a role for hypoxia-inducible genes in metastasis to and colonization of the bone marrow. This review will explore the role of hypoxia-regulated factors in bone development and remodeling, and how these elements may contribute to solid tumor metastasis to the bone.

Original publication

DOI

10.1016/j.pharmthera.2015.02.002

Type

Journal article

Journal

Pharmacol Ther

Publication Date

06/2015

Volume

150

Pages

169 - 177

Keywords

Bone metastasis, Bone microenvironment, HIF, Hypoxia, PHD, Remodeling, Antineoplastic Agents, Bone Development, Bone Neoplasms, Bone Remodeling, Cell Hypoxia, Humans, Hypoxia-Inducible Factor 1, Molecular Targeted Therapy, Prolyl Hydroxylases, Tumor Microenvironment, Von Hippel-Lindau Tumor Suppressor Protein